|Study Description:||The goal of the Phase I part of this clinical research study is to find the |
highest tolerable dose of a combination of dasatinib, cetuximab, and FOLFOX
(5-fluorouracil [5-FU], leucovorin [LV], and Eloxatin [oxaliplatin]) that can
be given to patients with metastatic colorectal cancer. The safety of these
drugs in combination will also be studied.
The goal of the Phase II part of this clinical research study is to learn if
dasatinib given in combination with FOLFOX with or without cetuximab can help
to control metastatic colorectal cancer.